iifl-logo-icon 1
iifl-logo-icon 1
iifl-logo-icon 1
Home

Suven Life Sciences Ltd Share Price

₹131.73
(5.00%)
Jul 22, 2024|02:14:09 PM

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Equities

Futures

Option

  • Open₹125.5
  • Day's High₹131.73
  • 52 Wk High₹144.8
  • Prev. Close₹125.46
  • Day's Low₹122.66
  • 52 Wk Low ₹60.75
  • Turnover (lac)349.8
  • P/E0
  • Face Value₹1
  • Book Value₹38.77
  • EPS0
  • Mkt. Cap (Cr.)₹2,872.69
  • Div. Yield0
No Records Found

Suven Life Sciences Ltd KEY RATIOS

Sector

Pharmaceuticals

Open

₹125.5

Prev. Close

₹125.46

Turnover(Lac.)

₹349.8

Day's High

₹131.73

Day's Low

₹122.66

52 Week's High

₹144.8

52 Week's Low

₹60.75

Book Value

₹38.77

Face Value

₹1

Mkt Cap (₹ Cr.)

2,872.69

P/E

0

EPS

0

Divi. Yield

0

Suven Life Sciences Ltd Corporate Action

9 May 2023

12:00 AM

AGM

Announcement Date: 09 May, 2023

arrow

9 May 2023

12:00 AM

BookCloser

arrow

29 Apr 2024

12:00 AM

Board Meeting

Agenda : Audited Result

arrow

Suven Life Sciences Ltd NEWS AND UPDATE

No data found

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

Knowledge Center

Demat Account

View More

Trading Account

View More

Suven Life Sciences Ltd SHAREHOLDING SNAPSHOT

22 Jul, 2024|02:34 PM
Jun-2024Mar-2024Dec-2023Sep-2023
  • Foreign Promoter
  • Indian Promoter
  • Institutions
  • Non Institutions
  • Custodies

Promoter- 70.26%

Foreign: 0.00%

Indian: 70.26%

Non-Promoter- 1.61%

Institutions: 1.61%

Non-Institutions: 28.11%

Custodian: 0.00%

Read More
Share Price

Suven Life Sciences Ltd FINANCIALS

Balance Sheet

Profit & Loss

Cash Flow

Ratios

Results

Loading...
Y/e 31 Mar( In .Cr)Mar-2024Mar-2023Mar-2022Mar-2021

Equity Capital

21.81

21.81

14.54

49.65

Preference Capital

0

0

0

0

Reserves

823.57

831.64

461.44

352.01

Net Worth

845.38

853.45

475.98

401.66

Minority Interest

View Balance Sheet
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Revenue

11.84

13.47

14.41

625.25

yoy growth (%)

-12.12

-6.49

-97.69

15.03

Raw materials

0

0

0

-153.7

As % of sales

0

0

0

24.58

Employee costs

-17.46

-15.28

-14.59

-58.73

View Profit & Loss
Loading...
Y/e 31 Mar( In .Cr)Mar-2022Mar-2021Mar-2020Mar-2018

Profit before tax

-36.24

-27.95

-25.93

230.26

Depreciation

-4.39

-4.34

-4.16

-21.3

Tax paid

0

5.32

12.18

-71.83

Working capital

-73.46

43.42

-154.2

81.51

Other operating items

View Cash Flow
Loading...
Y/e 31 MarMar-2022Mar-2021Mar-2020Mar-2018

Growth matrix (%)

Revenue growth

-12.12

-6.49

-97.69

15.03

Op profit growth

19.95

-13.37

-115.13

40.86

EBIT growth

31.61

6.86

-110.81

42.32

Net profit growth

60.16

64.55

-108.68

28.3

View Ratios
Particulars (Rupees in Crores.)Mar-2024Mar-2023Mar-2022Mar-2021Mar-2020

Gross Sales

11.69

13.54

11.84

13.48

14.41

Excise Duty

0

0

0

0

0

Net Sales

11.69

13.54

11.84

13.48

14.41

Other Operating Income

0

0

0

0

0

Other Income

28.59

14.45

5.32

7.75

14.04

View Annually Results

Suven Life Sciences Ltd Peer Comparison

Company Name
LTP
(₹)
P/E
(%)
Mkt.Cap
(₹Cr.)
NP Qtr
(₹Cr.)
Div.Yield
(%)
Sales Qtr
(₹.Cr)
Book Value
(₹)

Sun Pharmaceuticals Industries Ltd

SUNPHARMA

1,568.65

123.313,76,323.69867.60.865,536.9998.75

Divis Laboratories Ltd

DIVISLAB

4,519.8

76.171,19,994.455310.662,259507.93

Cipla Ltd

CIPLA

1,485.5

32.291,19,928.541,038.40.573,444.92346.41

Zydus Lifesciences Ltd

ZYDUSLIFE

1,144.45

33.511,15,173.541,405.20.263,172.6156.19

Dr Reddys Laboratories Ltd

DRREDDY

6,636

25.851,10,759.071,034.80.65,081.81,458.96

Figures of Market Capital(Mar Cap), Quarterly Net Profit(NP Qtr) and Quarterly Sales(Sales Qtr) are in ₹ Cr.

View All Peer Comparision

MORE ABOUT Suven Life Sciences Ltd

Management

Register Office

Registrar Office

Chairman & CEO

Venkateswarlu Jasti

Whole-time Director

Sudha Rani Jasti

Non Executive Director

Seyed E Hasnain

Independent Director

Santanu Mukherjee

Independent Director

J A S Padmaja

Company Sec. & Compli. Officer

Shrenik Soni

Independent Director

V Sambasiva Rao

Registered Office

Tel: -

Website: -

Email: -

Registrar Office

Tel: -

Website: -

Email: -

Reports by Suven Life Sciences Ltd

Summary

Suven Life Sciences Limited, erstwhile Suven Pharmaceuticals (SPL), is in the business of Contract Research And Manufacturing Services (CRAMS, catering to the needs of global life science industry and fine chemical majors. Suvens CRAMS provide innovative process research and development, supplies to clinical trials, rapid response pilot scale manufacture, dedicated commercial manufacturing on an exclusive basis. The company services include Custom Synthesis, Process R&D, Scale Up and Contract Manufacturing of intermediates, APIs and formulations. Suven Life Sciences has graduated from contract research to Collaborative Research transitioning from project-based transactions into relationship-based business. The Company has two international wholly owned subsidiary companies and one Indian wholly owned subsidiary company as on 31st March 2019. Suven Life Sciences Limited began operations in 1989 as specialty chemicals provider. Incorporated in Mar.89 as a private limited company, Suven Pharmaceuticals (SPL) was converted into a public limited company in Jan.95. It was promoted by Sudharani Jasti and Venkateswarlu Jasti, who is the present Chairman & CEO of the company. In March 1995, SPL came out with a public issue of 9.8 lac equity shares at a premium of Rs 40 aggregating Rs 4.9 cr to part-finance the companys project for the manufacture of bulk drugs and drug intermediates and meet long-term working capital requirements totalling to Rs 6.43 cr. During 1999-2000, the company
Read More

Company FAQs

What is the Suven Life Sciences Ltd share price today?

Down Arrow

The Suven Life Sciences Ltd shares price on N/A is Rs.₹131.95 today.

What is the Market Cap of Suven Life Sciences Ltd?

Down Arrow

Market capitalization, short for market cap, is the market value of a publicly traded company's outstanding shares. The market cap of Suven Life Sciences Ltd is ₹2877.48 Cr. as of 22 Jul ‘24

What is the PE and PB ratio of Suven Life Sciences Ltd?

Down Arrow

The PE and PB ratios of Suven Life Sciences Ltd is 0 and 3.24 as of 22 Jul ‘24

What is the 52 Week High and Low of Suven Life Sciences Ltd?

Down Arrow

The 52-week high/low is the highest and lowest price at which a Suven Life Sciences Ltd stock has traded during that given time period (similar to 1 year) and is considered as a technical indicator. The 52 week high and low of Suven Life Sciences Ltd is ₹60.96 and ₹145 as of 22 Jul ‘24

What is the CAGR of Suven Life Sciences Ltd?

Down Arrow

Suven Life Sciences Ltd's CAGR for 5 Years at 61.96%, 3 Years at 15.32%, 1 Year at 98.74%, 6 Month at 6.52%, 3 Month at 17.56% and 1 Month at 30.18%.

What is the shareholding pattern of Suven Life Sciences Ltd?

Down Arrow

The shareholding pattern of Suven Life Sciences Ltd is as follows:
Promoters - 70.27 %
Institutions - 1.62 %
Public - 28.12 %

QUICKLINKS FOR Suven Life Sciences Ltd

Information
Share PriceFutures PriceOption Chain
Financials
Profit & LossBalance SheetCash FlowKey Ratios
Results
Quarterly ResultHalf Yearly ResultNine Monthly ResultAnnual Result
News
Company
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Marketplus
Derivativesplus
IPOplus
Mutual Fundsplus
Calculatorsplus
Nifty 50plus
Companyplus
Loansplus
Knowledge Centerplus
Newsplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

About
IIFL Group
Products & Services
Trading Documentation
Useful Links
ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.